Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Neuralstem Inc announces final results of phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology


Monday, 17 Mar 2014 09:15am EDT 

Neuralstem Inc:Final results from Phase I safety trial using NSI-566 spinal cord stem cells in treatment of amyotrophic lateral sclerosis were published in peer-reviewed journal, Annals of Neurology.In Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcomes, results were updated from Phase I interim data, reported earlier, to include data from the last six patients in the trial.These six patients were first to receive cervical stem cell transplants.Three of them were also first to be transplanted along length of their spines, in both the lumbar and the cervical regions.Results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy.Researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits.This is consistent with the hypothesized neuroprotective mechanism-of-action for this cell therapy.Since concluding Phase I, trial has progressed to Phase II at three centers which treated its first patient in February.Treatment of three of five Phase II cohorts has been completed. 

Company Quote

2.75
0.05 +1.85%
26 Dec 2014